Table 1.
Characteristics of Patients with Morphea-like cGvHD Exhibiting an Isomorphic Response (continued on following page)
| Gender/Age | Primary diagnosis | Date of skin evaluation (days post transplant) | Type of allogeneic transplant | cGvHD other organ involvement | Type of cutaneous cGvHD | Current cGvHD treatment | Biopsy at site of isomorphic lesion | Location of isomorphic response |
|---|---|---|---|---|---|---|---|---|
| M/57 | CLL | Day +1611 | 6/6 NM related PBSCT | GI
Oral |
D/S/F | MMF 1500mg BID
Prednisone 25/0mg alternate days |
No | WB |
| M/56 | MM | Day +763 | 6/6 NM related PBSCT | None | D/S/F | None | Yes | WB |
| F/52 | MM | Day +541 | 6/6 NM related PBSCT | Oral
VV |
E/D | Clobetasol ointment 0.05% | No | BB
WB |
| F/39 | NHL | Day +1972 | 6/6 NM related PBSCT | Ocular
Oral VV |
E/D/S/F | ECP
Hydroxychloroquine 600mg QD Prednisone 35mg QOD Tacrolimus 1mg QAM; 0.5 mg QPM |
No | WB |
| F/20 | Precursor
B cell ALL |
Day +789 | 6/6 Myelo. related BMT | Ocular
Oral Pulmonary |
D/S | MMF 1500mg q12hrs
Prednisone 100 mg QD |
No | BB
WB |
| M/57 | MDS | Day +1647 | 6/6 Myelo. related PBSCT | Ocular
Oral |
E/D/S/F | ECP
MMF 1gm q12hrs Prednisone 20mg QOD Tacrolimus 4mg q12hrs |
No | WB |
| F/53 | MM | Day +2436 | 6/6 NM related PBSCT | Ocular
VV |
E/D | Prednisone 50/40mg alternate days | Yes | WB |
| M/36 | CML | Day +1203 | 6/6 Myelo. related BMT | Ocular
Oral |
E/D/S | MMF 500mg BID
Tacrolimus 2mg BID |
Yes | WB |
| M/40 | Precursor
B cell ALL |
Day +2835*
Day +1417** |
6/6 Myelo. unrelated BMT | GI
Hepatic Ocular Oral |
E/D/S/F | Prednisone 10mg QD
Tacrolimus 0.5 mg QD |
Yes | WB |
| F/46 | NHL | Day +944 | 6/6 NM related PBSCT | Ocular
Oral |
E/D/S/F | Prednisone 60/10mg alternate days
Sirolimus 1mg QD Tacrolimus 4mg QD |
Yes | BB
WB |
| F/49 | NHL | Day +1106 | 6/6 Myelo. related PBSCT | Ocular
Oral |
E/D/S/F | None | Yes | WB |
Abbreviations: ALL, acute lymphoblastic leukemia; BB, brassiere-band area; BMT, bone marrow transplant; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; ECP, extracorporeal photopheresis, MDS, myelodysplastic syndrome, MM, multiple myeloma, MMF, mycophenolate mofetil, Myelo, myeloablative, NHL, non-Hodgkin’s lymphoma, NM, non-myeloablative, PBSCT, peripheral blood stem cell transplant, VV, vulvovaginal, WB, waistband area.
Classification of cutaneous cGvHD: E, erythematous-type cGvHD; D, morphea-like sclerosis; S, subcutaneous sclerosis; F, fasciitis.
T-cell depleted 6/6 Myelo unrelated BMT
T-cell repleted 6/6 Myelo unrelated BMT (second transplant; same donor)